化瘀通痹方对糖尿病合并下肢动脉硬化闭塞症患者血清CRP、IL-6水平的疗效观察

发布时间：2018-01-01 12:38

本文关键词：化瘀通痹方对糖尿病合并下肢动脉硬化闭塞症患者血清CRP、IL-6水平的疗效观察　出处：《山西中医学院》2016年硕士论文　论文类型：学位论文

【摘要】：目的通过观察验方化瘀通痹方对糖尿病并发下肢动脉硬化闭塞症患者早期临床症候积分、各项临床客观指标的影响及疗效,探讨其作用机制。为化瘀通痹方可以降低患者血清炎性因子CRP、IL-6水平,抑制血栓形成,缓解患者临床症状提供依据,指导患者临床用药。方法将75名糖尿病并发下肢动脉硬化闭塞症患者随机分为治疗组(40例),对照组(35例),两组在降糖、调脂、降压、抗血小板聚集的基础上,同时分别给予患者治疗组化瘀通痹方加前列地尔注射液,对照组单独前列地尔注射液治疗,疗程31天,观察患者治疗前后的临床症候积分和疗效,检测患者部分血清炎性因子C反应蛋白(CRP)、白细胞介素6(IL—6)及糖化血红蛋白(Hb Ac)、空腹血糖(FPG)、餐后两小时血糖(2hPG)、血脂(TG、TC、LDL-C、HDL-C)、血液流变学指标、双下肢动脉血管内径及血液流动峰速的变化。结果1治疗组临床总有效率92.1%,明显优于对照组总有效率的75%。2与各自治疗前相比两组治疗后能有效改善患者的糖化血红蛋白、空腹血糖、餐后2h血糖、血脂(TC、TG、LDL-C、HDL-C)、血流变、炎性因子(CRP、IL-6)、双下肢动脉的血管内径和血流峰速水平,P0.05,差异有统计学意义。3两组治疗后比较炎性因子、血流变系列、双下肢动脉的血管内径和血流峰速水平,P0.05,差异有统计学意义,且治疗组疗效优于对照组。4两组患者治疗前后血常规、尿常规,肝功、肾功比较,P0.05,无统计学差异。所有入选病例未发生药物不良反应和不良事件。结论以益气养阴,活血通络为治疗法则的验方化瘀通痹方,对糖尿病合并下肢动脉硬化闭塞症的早期干预及预防进一步发展有重要意义,可以降低患者的血糖,降低血清炎性因子,调节患者的脂代谢,辅助改善患者的血流变水平,降低患者双下肢动脉血流峰值速度,增宽血管内径,进而增加斑块稳定,减少血栓形成而栓塞、坏死。化瘀通痹方联合前列地尔对于早期糖尿病并发下肢动脉粥样硬化闭塞症的治疗是安全可行地。
[Abstract]:Objective To observe the experience of Huayu Tongbi early clinical symptoms points in patients with occlusion of the lower extremity diabetic atherosclerosis, effects of various clinical indexes and curative effect, to explore the mechanism of Tongbi. For removing blood stasis can reduce serum inflammatory factors in patients with CRP, IL-6 level, inhibit thrombosis, alleviate the clinical symptoms of the patients and provide the basis and the medication guide. Methods 75 diabetic patients with lower extremity arterial occlusive disease were randomly divided into treatment group (40 cases) and control group (35 cases), two groups in hypoglycemic, lipid-lowering, antihypertensive, anti platelet aggregation, while patients in treatment group were given Tongbi Huayu with Alprostadil Injection, the control group alone Alprostadil Injection treatment course of 31 days, to observe the clinical symptoms and curative effect of the patients before and after treatment, detection of patients serum inflammatory factors of C reaction protein (CRP), interleukin - 6 (IL - 6) and glycosylated hemoglobin (Hb Ac), fasting blood glucose (FPG), two hour postprandial blood glucose (2hPG), blood lipids (TG, TC, LDL-C, HDL-C), blood rheology, changes in the lower limbs artery diameter and blood flow velocity peak. Results of the 1 clinical treatment group the total efficiency of 92.1%, significantly better than the control group the total efficiency of 75%.2 before treatment compared with respective two groups after treatment can effectively improve HbA1c, fasting glucose, 2h postprandial blood glucose, blood lipids (TC, TG, LDL-C, HDL-C), blood rheology, inflammatory factors (CRP, IL-6), blood vessel diameter and the peak flow velocity level, lower extremity artery P0.05, there was a significant difference between the two groups of.3 after treatment of inflammatory factors, blood rheology, blood vessel diameter and blood flow velocity peak level, lower extremity artery P0.05, the difference was statistically significant, and the effect of the treatment group than the control group before and after.4 treatment in two groups of blood. Urine routine, liver function, kidney Power, P0.05, there was no significant difference in all patients without adverse drug reactions and adverse events. Conclusion to Yiqi, Huoxue Tongluo Huayu treatment for inspection law of Tongbi, has important significance of lower extremity arterial occlusive disease of diabetic patients for early intervention and prevention of further development, can reduce the patients blood glucose, serum inflammatory factor, regulate lipid metabolism of patients, improve the patient's blood level of auxiliary variable, reduce the patients with lower extremity artery blood flow velocity, widened vessel diameter, and increase plaque stability, reduce thrombosis and embolism, necrosis. Blood stasis Tongbi combined with alprostadil is safe and feasible for the treatment of early diabetic patients with lower extremity atherosclerotic occlusive disease.

【学位授予单位】：山西中医学院
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】